azomycin has been researched along with Pancreatic Neoplasms in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernards, N; De Souza, R; Fitzgerald, JB; Fricke, IB; Hendriks, BS; Klinz, SG; Lee, H; Ventura, M; Zheng, J | 1 |
| Brender, JR; Chandramouli, GVR; Kishimoto, S; Krishna, MC; Mitchell, JB; Saida, Y; Yamamoto, K | 1 |
| Alonso-Gordoa, T; Benavent, M; Capdevila, J; Custodio, A; Díez, JJ; Gajate, P; García-Carbonero, R; Grande, E; Hernando, J; Lanillos, J; López, C; Molina-Cerrillo, J; Rodriguez-Antona, C; Santos, M; Sevilla, I; Teulé, A | 1 |
| Andersen, LMK; Galappathi, K; Gaustad, JV; Hauge, A; Rofstad, EK; Simonsen, TG; Wegner, CS | 1 |
| Adam, ASA; Boulghourjian, A; Caldon, CE; Cazet, AS; Conway, JRW; Croucher, DR; Da Silva, AM; Del Monte-Nieto, G; Haigh, JJ; Harvey, RP; Herrmann, D; Killen, MJ; Magenau, A; Mélénec, P; Morton, JP; Murphy, KJ; Nobis, M; Pajic, M; Pinese, M; Sansom, OJ; Shearer, RF; Timpson, P; Vennin, C; Wang, Y; Warren, SC; Zaratzian, A | 1 |
| Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE | 1 |
| Bailey, KM; Baker, AF; Cornnell, HH; Gillies, RJ; Hart, CP; Ibrahim-Hashim, A; Leos, R; Martinez, GV; Wojtkowiak, JW; Zhang, X | 1 |
| Dhani, NC; Gallinger, S; Hedley, DW; Hill, RP; Pintilie, M; Schwock, J; Serra, S; Xu, J | 1 |
| Dhani, NC; Green, D; Hedley, DW; Jaffray, D; Metran-Nascente, C; Metser, U; Milosevic, M; Vines, DC; Yeung, I | 1 |
| Baker, AF; Cornnell, HH; Gillies, R; Hart, CP; Martinez, GV; Wojtkowiak, JW; Zhang, X | 1 |
| Pourmorteza, M; Rahman, ZU; Young, M | 1 |
| Cao, P; Do, T; Hedley, DW; Hill, RP; Lohse, I; Pintilie, M; Rasowski, J; Tsao, MS | 1 |
| Hirota, M; Kikuta, K; Masamune, A; Satoh, K; Shimosegawa, T; Watanabe, T | 1 |
| Batmunkh, E; Hori, H; Miyake, K; Nagasawa, H; Nishioka, M; Shimada, M; Sugimoto, K; Uto, Y | 1 |
| Baker, AF; Cárdenas-Rodríguez, J; Cornnell, H; Galons, JP; Gillies, RJ; Li, Y; Pagel, MD | 1 |
| Büchler, MW; Büchler, P; Friess, H; Hines, OJ; Lavey, RS; Reber, HA; Tomlinson, J | 1 |
| Courtenay, VD; Mills, J; Peacock, JH; Rose, CM; Spooner, D; Stephens, TC | 1 |
| Abe, M; Hosotani, R; Imamura, M; Manabe, T; Nishimura, Y; Ohshio, G; Shibamoto, Y | 1 |
| Courtenay, VD; Smith, IE; Steel, GG | 1 |
| Munzenrider, JE | 1 |
2 review(s) available for azomycin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Topics: Antineoplastic Agents; Humans; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Hypoxia | 2016 |
Recent advances in radiotherapy.
Topics: Breast Neoplasms; Bromodeoxyuridine; Carcinoid Tumor; Elementary Particles; Fast Neutrons; Hot Temperature; Humans; Male; Melanoma; Metronidazole; Neoplasms; Nitroimidazoles; Pancreatic Neoplasms; Prostatic Neoplasms; Protons; Radiation Protection; Radiation Tolerance; Radiation-Sensitizing Agents; Radioisotopes; Radiotherapy Dosage; Radiotherapy, High-Energy; Rectal Neoplasms; Salivary Gland Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1977 |
4 trial(s) available for azomycin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Topics: Humans; Middle Aged; Neoplasms, Second Primary; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Progression-Free Survival; Sunitinib | 2021 |
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2015 |
Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.
Topics: Adult; Analysis of Variance; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Feasibility Studies; Female; Humans; Immunohistochemistry; Indicators and Reagents; Injections, Intravenous; Male; Nitroimidazoles; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Premedication; Selection Bias | 2015 |
A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Combined Modality Therapy; Female; Humans; Intraoperative Care; Male; Middle Aged; Nitroimidazoles; Osteosarcoma; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 1997 |
14 other study(ies) available for azomycin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Topics: Animals; Cell Hypoxia; Female; Fluorine Radioisotopes; Irinotecan; Liposomes; Longitudinal Studies; Mice; Mice, Inbred NOD; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms, Experimental; Nitroimidazoles; Oxidation-Reduction; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs | 2021 |
Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.
Topics: Animals; Carcinoma, Pancreatic Ductal; Contrast Media; Extracellular Fluid; Female; Heterocyclic Compounds; Heterografts; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neoplasm Transplantation; Nitroimidazoles; Organometallic Compounds; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Pressure; Tumor Microenvironment | 2017 |
Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.
Topics: Animals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Fluorescence Resonance Energy Transfer; Humans; Hypoxia; Intravital Microscopy; Mice; Mice, Inbred BALB C; Morpholines; Nanoparticles; Nitroimidazoles; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoramide Mustards; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Transplantation, Heterologous; Tumor Microenvironment | 2018 |
Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood Circulation; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Humans; Hydralazine; Hydrogen-Ion Concentration; Mice; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake.
Topics: Aged; Aged, 80 and over; Algorithms; Female; Humans; Hypoxia; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Nitroimidazoles; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Regional Blood Flow | 2016 |
MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Female; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Time Factors; Xenograft Model Antitumor Assays | 2016 |
Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Humans; Mice; Neoplastic Stem Cells; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer.
Topics: Animals; Cell Hypoxia; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Fibrosis; Humans; Neovascularization, Pathologic; Nitroimidazoles; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2008 |
The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancer.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Neovascularization, Pathologic; Nitroimidazoles; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2008 |
Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Female; Mice; Mice, SCID; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model.
Topics: Abdominal Neoplasms; Animals; Cell Hypoxia; Cell Line, Tumor; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Nitroimidazoles; Oxygen; Pancreatic Neoplasms; Partial Pressure; Staining and Labeling | 2004 |
Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Pancreatic Neoplasms; Transplantation, Heterologous | 1981 |
The effect of misonidazole on the radiation response of clonogenic human pancreatic carcinoma cells.
Topics: Animals; Cell Survival; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Oxygen; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Time Factors; Transplantation, Heterologous | 1978 |